Ambrilia Biopharma Inc.

Ambrilia Biopharma Inc.

October 23, 2007 12:30 ET

Ambrilia Biopharma Inc.: PCK3145 Clinical Data From the MSKCC Phase I/II Study Presented at Leading Scientific Conferences

MONTREAL, QUEBEC--(Marketwire - Oct. 23, 2007) - Ambrilia Biopharma (TSX:AMB) announced today that the data of the Phase I/II clinical study conducted at the Memorial Sloan Kettering Cancer Centre (MSKCC) in New York City, was presented by Dr. Susan Slovin, co-investigator of the study, at the AACR-NCI-EORTC International Conference and by Dr. Chandra Panchal at the 2007 Annual Fall Conference on Antiangiogenesis.

Ambrilia had announced previously on April 24, 2007, findings of the MSKCC study which indicated that the therapeutic peptide drug PCK3145 had shown evidence of clinical activity in metastatic prostate cancer patients.

Poster/presentation session details:

AACR-NCI-EORTC International Conference, October 22-26, San Francisco, CA

PCK3145 - A Novel Multitargeted Signaling Agent for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)

Poster Session A

Antiangiogenic / Antivascular Agents

Presenter: Dr. Susan F. Slovin, Associate Attending Physician, Memorial Sloan Kettering Cancer Centre

A copy of the poster will be available at

2007 Annual Fall Conference on Antiangiogenesis, New Frontiers in Therapeutic Development, October 22-23, Cambridge, MA

PCK3145 - A Novel Multitargeted Signaling Peptide Derived from a Naturally Occurring Protein, for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)

Session 1: New Targets and Strategies

Presenter: Dr. Chandra Panchal, Executive Vice-President, Business Development, Licensing and IP, Ambrilia


Prostate cancer is one of the most common cancers worldwide and the leading cancer in men in North America and Europe. According to the American Cancer Society, it is estimated that over 234,000 new cases will occur in the United States during 2007 and more than 27,000 men will die from prostate cancer in the same year


PCK3145 is a synthetic 15-mer peptide that is derived from the natural sequence of amino acids of the prostate secretory protein (PSP94), one of three predominant proteins found in human seminal fluid. PSP94 expression in the prostate is down regulated in patients with advanced prostate cancer, and believed to be a survival mechanism for the cancer cells. Results from an earlier trial conducted in the U.K. showed PCK3145 to be safe and well tolerated at all doses tested and further suggest that it also plays a role in preventing the metastatic process as measured by its effect on MMP-9 levels, a Gelatinase B enzyme involved in angiogenesis, tumor invasion and metastasis. The mechanism of action and receptor for PCK3145 suggests PCK3145 to be a signal transduction inhibitor with multiple ways (apoptosis, anti-angiogenesis and anti-metastasis) to restrict disease development.

Ambrilia's forward-looking statements

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the Company's filings. We refer you to the Risk Factors section of the Company's Management's Discussion & Analysis of Financial Condition and Results of Operations which contain a more exhaustive analysis of the risks and uncertainties that are generally connected to the business of the Company. Such statements are also based on various assumptions, including the successful and timely completion of clinical studies on Ambrilia's products demonstrating efficacy and safety for human use, their successful commercialization within the forecasted timelines and the attainment of the forecasted milestone payments and other revenues. While Ambrilia anticipates that subsequent events and developments may cause Ambrilia's views to change, Ambrilia specifically disclaims any obligation to update these forward looking statements, unless obligated to do so by applicable securities laws.


Ambrilia Biopharma Inc. (TSX:AMB) is a biopharmaceutical company dedicated to the discovery and development of novel treatments for viral diseases and cancer. Ambrilia's product portfolio includes an HIV protease inhibitor program (with lead compound PPL-100), an HIV integrase inhibitor program, two new formulations of existing peptides (Octreotide and Goserelin), other tumor targeted peptides such as PCK3145 and the Tumor and tumor Vasculature Targeting (TVT) technology platform, as well as other anti-viral programs. Exclusive worldwide rights to PPL-100 and its related compounds have been granted to Merck & Co., Inc. in return for milestone payments and royalties. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France. For more information, please visit the Company's web site:

Contact Information